Sumanta K Pal

..These trial results pose legitimate questions regarding the future application of anthracyclines in the adjuvant breast cancer setting...

..Herein we attempt to characterize the QOL in long-term survivors who received high-dose paclitaxel, etoposide, carboplatin, and ifosfamide (TECTIC)...

..Although the development of biomarkers to guide therapy for mCRPC is ideal, there are inherent challenges in establishing biomarker-driven treatment...

..In the setting of de novo MBC, large registry analyses cite positive temporal trends in survival, but the extent to which advances in systemic therapy have contributed to these gains is not clear...

..We sought to compare clinical outcomes in patients treated for MIBC with neoadjuvant CG and MVAC at our institution...

..The current review will outline the development pathway of tivozanib to date, and offer lessons learned and future opportunities...

..Although VEGF and mTOR inhibition have dramatically improved outcomes for patients with mRCCs, a surge above the current plateau with these agents will likely require exploring new avenues...

..This review describes in detail the preclinical and clinical development of cabazitaxel...

..Ultimately, head-to-head trials comparing targeted therapies are necessary to resolve clinical equipoise. Several ongoing efforts juxtaposing the approved agents for mRCC are discussed...

..More recently, several agents have been developed that antagonize Akt--these agents are in various stages of clinical testing...

..Herein, the clinical relevance of putative RCC biomarkers is examined in detail...

..The clinical characteristics of TNBC and clinical experience to date with novel targeted agents under development for this aggressive phenotype is reviewed...

..The application of mTOR inhibitors in unique populations is also described...

..Herein, the clinical development of novel therapies for NSCLC is described, including some discussion of relevant biomarkers and determination of synergy with both cytotoxic therapy and other targeted agents...

..The scarcity of information underscores the need for further treatment- and outcome-related studies in papillary carcinoma of the breast...

..Finally, available cost-effectiveness data for targeted therapies in mRCC are presented. The amalgam of these studies may offer the oncologist greater clarity in clinical decision-making...

..Clinical tools such as the geriatric assessment and biologic assays, such as the 21-gene recurrence score, may ultimately play a role in treatment algorithms for this unique demographic...

..Finally, preclinical studies provide a signal of potential activity with use of heat shock protein 90 (Hsp90) and Src inhibitors in this breast cancer subtype...

..The current review explores both the implications and potential caveats of this innovative trial. CALGB 49907 represents a paradigm for further studies of adjuvant cancer therapy in older adults...

..On the basis of these compelling data, both abiraterone and MDV3100 will be examined in the phase III setting...

..Ultimately, tools such as the Comprehensive Geriatric Assessment (CGA) that account for physiological (as opposed to chronological) age may prove useful in the evaluation and treatment of older adults with mRCC...

..This article details the efficacy and safety of these agents to provide a framework for their clinical use...

..The goal of the current study is to understand the effect of patient age and health status on oncologists' decision to recommend adjuvant treatment (endocrine therapy and chemotherapy) in older women with HR-positive breast cancer...

..It has been approved in the management of metastatic colorectal cancer, non-small cell lung cancer, renal cancers, and recurrent glioblastoma multiforme...

..Of these, 55 possessed a number of patients (i.e., greater than 10) deemed worth of the current analysis. Beyond outlining these datasets, we discuss the relevance of clinical and pathologic endpoints in assessing preoperative therapy...

....

..This article serves as a review of the available evidence in the evaluation, treatment, and support of the older adult with cancer...

..Analyzing tumor-free lymph nodes from cancer patients shows elevated myeloid infiltrates, STAT3 activity, and increased survival signal...

....

..We sought to determine whether survival has improved for patients with mRCC diagnosed in the era of targeted therapies, as compared to the era of immunotherapy...

..In this review we summarize the efficacy of neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer based on currently published studies...

..The 4-miRNA is associated with ccRCC metastasis and prognosis. The signature is ready for and will benefit from further large clinical cohort validation and has the potential for clinical application...

..This article describes the preclinical and clinical evolution of axitinib, with an emphasis on its development and role in mRCC...

..Taken together, age, sex, and comorbidity each encompass a complex array of physiologic and molecular variations that may each aid in personalizing care for the patient with cancer...

..Recent data suggest a synergistic interaction of HER2 epitope-targeting agents when used in combination...

..Herein, we explore the relationship of mTOR to lung carcinogenesis and further describe clinical trials of mTOR inhibitors alone and in combination with chemotherapeutic and targeted agents...

..Individualization of care in the setting of a sound oncologic framework may optimize the risk/benefit ratio within individual patient cohorts...

..This review describes key studies from the geriatric literature that provide principles for assessing health status in the older patient, and ways that these principles can be applied to oncology care in an older population are proposed...

....

..We explore genetic and molecular rationales for an association between these metabolic and neoplastic processes...